Our Company
Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, especially antibody-drug conjugates (ADC) and bispecific antibodies. Leveraging its proprietary patient-derived cell-based antibody discovery technology and translational research expertise, AimedBio is at the forefront of creating innovative therapies designed to target and effectively treat cancer.
Conventional chemotherapy for cancer is a powerful treatment but there are many unwanted adverse effects as chemotherapy agents cannot differentiate cancer cells from healthy cells. Antibody, on the other hand, can be delivered specifically to its target, but have limited potency. Combining only the advantages of these two therapeutics, ADCs are designed to specifically bind to their target cells and deliver toxin payload directly into these cells, minimizing off-target killing of healthy cells and unwanted side-effects.
PRO: powerful treatment
CON: unwanted adverse effect by
also killing healthy cells
PRO: delivery to specific targets
CON: treatment effect not as
potent as chemotherapy
specifically bind to target cells
to directly deliver
powerful toxin payload
ADCs are composed of:
- 1) Antibody Antibody that binds a specific antigen on the surface of target cells;
- 2) Linker molecule which functions as a stable bridge between the antibody and the payload; and
- 3) Potent toxin payloads which induce cell killing.
Videos of AimedBio
